Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Dexmedetomidine and Buccal Midazolam for Acute Agitation
NCT06752616Phase 3Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexmedetomidine and midazolam in agitation (3 arms). Primary endpoint: Positive and Negative Syndrome Scale - Excited Component at 60 minutes. Started Dec 2024; status: recruiting.
02
Drugs
dexmedetomidinemidazolam
03
Conditions
agitation
Beyond the preview
Go deeper on NCT06752616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752616.